Literature DB >> 31891296

Malignant Hyperthermia: A Case Study in the Dental Ambulatory Surgery Setting.

Bryant W Cornelius1, Shelby Olsen Dib2, Regina A Dowdy2, Christina K Horton3, Katherine Frimenko3, Shadee Mansour4, Farah Abu Sharkh4, Marcus T Joy5, David L Hall6, Hany A Emam7, Courtney A Jatana7, Kelly S Kennedy8.   

Abstract

Historically, patients who developed malignant hyperthermia had an extremely high rate of mortality. Today, if treated appropriately, patients who experience an episode of malignant hyperthermia will most likely survive. This dramatic decrease in mortality associated with malignant hyperthermia is due to several factors, including an increased understanding of the disease, improved diagnostic and monitoring equipment, and the development of lifesaving pharmacologic agents. This article presents the very likely case of acute malignant hyperthermia in a 24-year-old man with special needs, who presented for restorative dentistry under general anesthesia in the outpatient clinic of The Ohio State University's College of Dentistry.

Entities:  

Keywords:  Ambulatory surgery setting; Anesthesia complications; Dental anesthesia; Malignant hyperthermia

Mesh:

Year:  2019        PMID: 31891296      PMCID: PMC6938168          DOI: 10.2344/anpr-66-04-03

Source DB:  PubMed          Journal:  Anesth Prog        ISSN: 0003-3006


  16 in total

1.  Malignant Hyperthermia: A Case Report in a Trauma Patient.

Authors:  Ian C Gibbs; Oluwole Fadahunsi; Natoya Reid; Andrea M Bonnick
Journal:  J Oral Maxillofac Surg       Date:  2018-07-19       Impact factor: 1.895

Review 2.  Malignant hyperthermia: a statistical review.

Authors:  B A Britt; W Kalow
Journal:  Can Anaesth Soc J       Date:  1970-07

3.  Prevalence of malignant hyperthermia diagnosis in hospital discharge records in California, Florida, New York, and Wisconsin.

Authors:  Zhen Lu; Henry Rosenberg; Guohua Li
Journal:  J Clin Anesth       Date:  2017-03-14       Impact factor: 9.452

Review 4.  Malignant hyperthermia: pharmacology of triggering.

Authors:  P M Hopkins
Journal:  Br J Anaesth       Date:  2011-05-30       Impact factor: 9.166

Review 5.  Perioperative management of the paediatric patient with coexisting neuromuscular disease.

Authors:  J Lerman
Journal:  Br J Anaesth       Date:  2011-12       Impact factor: 9.166

6.  Dantrolene requires Mg2+ to arrest malignant hyperthermia.

Authors:  Rocky H Choi; Xaver Koenig; Bradley S Launikonis
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-03       Impact factor: 11.205

7.  Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006.

Authors:  Marilyn Green Larach; Gerald A Gronert; Gregory C Allen; Barbara W Brandom; Erik B Lehman
Journal:  Anesth Analg       Date:  2010-02-01       Impact factor: 5.108

Review 8.  Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.

Authors:  Sheila Riazi; Natalia Kraeva; Philip M Hopkins
Journal:  Anesthesiology       Date:  2018-01       Impact factor: 7.892

9.  A clinical grading scale to predict malignant hyperthermia susceptibility.

Authors:  M G Larach; A R Localio; G C Allen; M A Denborough; F R Ellis; G A Gronert; R F Kaplan; S M Muldoon; T E Nelson; H Ording
Journal:  Anesthesiology       Date:  1994-04       Impact factor: 7.892

Review 10.  Malignant hyperthermia: a review.

Authors:  Henry Rosenberg; Neil Pollock; Anja Schiemann; Terasa Bulger; Kathryn Stowell
Journal:  Orphanet J Rare Dis       Date:  2015-08-04       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.